Australia Healthcare Providers & Services

Australian Clinical Labs Ltd (ACL)

Track

Track

Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Australian Clinical Labs Ltd. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Melinda McGrath Director
Transaction date
Purchase
Price
90.90
Quantity 74,129
Value A$4,818,254
Melinda McGrath Director
Transaction date
Purchase
Price
65.74
Quantity 96,380
Value A$1,329,041
Michael Philip Stanford Director
Transaction date
Sale
Price
434.57
Quantity 48,457
Value A$1,549,494
Melinda McGrath Director
Transaction date
Planned purchase
Price
4.27
Quantity 65,658
Value A$280,360
Michael Thomas Alscher Director
Transaction date
Planned purchase
Price
4.27
Quantity 24,574
Value A$104,931
Leanne Rowe Director
Transaction date
Sale
Price
4.30
Quantity 32,500
Value A$139,877
Michael Thomas Alscher Director
Transaction date
Planned purchase
Price
5.06
Quantity 5,928
Value A$29,996
Andrew Mark Rendle Dutton Director
Transaction date
Planned purchase
Price
5.06
Quantity 1,897
Value A$9,599
Melinda McGrath Director
Transaction date
Planned purchase
Price
5.06
Quantity 66,200
Value A$334,972
Michael Philip Stanford Director
Transaction date
Purchase
Price
4.62
Quantity 8,000
Value A$36,960
Mark Haberlin Director
Transaction date
Purchase
Price
4.40
Quantity 22,500
Value A$98,989
Melinda McGrath Director
Transaction date
Purchase
Price
3.64
Quantity 247,252
Value A$899,997
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-01-04 2023-12-20 B Purchase Melinda McGrath Director
74,129
90.90
A$4,818,254 		74,129 90.90 A$4,818,254
2023-03-17 2023-03-13 B Purchase Melinda McGrath Director
96,380
65.74
A$1,329,041 		96,380 65.74 A$1,329,041
2022-10-07 2022-10-04 S Sale Michael Philip Stanford Director
48,457
434.57
A$1,549,494 		48,457 434.57 A$1,549,494
2022-09-27 2022-09-15 PP Planned purchase Melinda McGrath Director
65,658
4.27
A$280,360 		65,658 4.27 A$280,360
2022-09-20 2022-09-15 PP Planned purchase Michael Thomas Alscher Director
24,574
4.27
A$104,931 		24,574 4.27 A$104,931
2022-09-13 2022-09-09 S Sale Leanne Rowe Director
32,500
4.30
A$139,877 		32,500 4.30 A$139,877
2022-04-28 2022-04-21 PP Planned purchase Michael Thomas Alscher Director
5,928
5.06
A$29,996 		5,928 5.06 A$29,996
2022-04-28 2022-04-21 PP Planned purchase Andrew Mark Rendle Dutton Director
1,897
5.06
A$9,599 		1,897 5.06 A$9,599
2022-04-28 2022-04-21 PP Planned purchase Melinda McGrath Director
66,200
5.06
A$334,972 		66,200 5.06 A$334,972
2022-02-28 2022-02-25 B Purchase Michael Philip Stanford Director
8,000
4.62
A$36,960 		8,000 4.62 A$36,960
2021-11-22 2021-11-22 B Purchase Mark Haberlin Director
22,500
4.40
A$98,989 		22,500 4.40 A$98,989
2021-05-25 2021-05-25 B Purchase Melinda McGrath Director
247,252
3.64
A$899,997 		247,252 3.64 A$899,997
Explore more

More insider trading research around Australian Clinical Labs Ltd

More insider trades in Australia
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Providers & Services companies with insider activity
Insider trading in Asia-Pacific